The UK’s Competition Appeal Tribunal made “fundamental errors” and tried to “fit its own world view” into a ruling that Auden, Actavis UK and Allergan unlawfully inflated the price of hydrocortisone tablets, the Court of Appeal of England and Wales has heard.
To read more
Subscribe to Global Competition Review
Register for limited access
Register for free to unlock full access to our Insight content, including Guides, Reviews and Hubs. Plus, get our newsletter straight to your inbox.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below